Study drug HH2853 for hard-to-treat lymphoma and solid cancers
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This Phase 1/2 trial tests the safety and early effectiveness of HH2853 in people whose cancer has come back or did not respond to prior treatment. It may help shrink tumors and guide future treatment for specific cancer types and genetic changes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re an adult (18 or older) and can sign informed consent
- Your cancer must be one of the allowed types (such as follicular lymphoma, PTCL, or specific solid tumors) and have been confirmed by a pathology test
- Your cancer must have had at least one prior treatment and then come back or keep growing, or there is no standard treatment option
- You must be able to take part in study testing, including having measurable tumor spots on scans (and archival tumor tissue when required)
- Your blood and organ tests must be within required ranges (bilirubin, liver enzymes, kidney function, blood counts, clotting)
- You must not have had certain treatments recently (chemo/small-molecule therapy/radiation within set time windows) or major recent procedures
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental drug called LP-284 in people with certain advanced lymphomas or solid tumors that have not responded to standard treatments. The goal is to see if it is safe and works against these cancers.
This trial tests a new drug called HCB301, which targets proteins that help cancer hide from the immune system. It is for people with advanced solid tumors or classical Hodgkin lymphoma who have tried other treatments without success.
This early-phase study tests whether HB0036 is safe and can work in people with advanced solid tumors (cancers) that have come back or spread and did not respond to standard treatments. You may be considered especially if your tumor matches certain tumor types and biomarker results.
This early-phase study tests HCB101, an immune-targeting drug, to see if it is safe and can shrink certain solid tumors or non-Hodgkin lymphoma. It may help people whose cancer has returned or stopped responding to standard treatments.
This Phase 1 trial tests HS-20089 in people with advanced solid cancers that have limited standard treatment options. It focuses on safety and early signs of whether the drug can shrink tumors or control them.
This trial tests an experimental drug, HH2853, for people with certain types of T-cell lymphoma that have come back or not responded to prior treatments. It aims to see if the drug is safe and effective.
Hear when a new Epithelioid Sarcoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.